Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Add To Watchlist

Recent & Breaking News (OTCQX:CSLLY)

Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease

PR Newswire November 2, 2020

Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children ?2 to <18 Years Old at the European Society for Paediatric Infectious Diseases (ESPID)

PR Newswire October 29, 2020

CSL Named as One of the World's Best Employers

PR Newswire October 29, 2020

Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020

PR Newswire October 21, 2020

Seqirus Announces Late-Breaking Data at IDWeek 2020: New Real-World Evidence Shows Value of Adjuvanted Influenza Vaccine for Adults 65 Years and Older with Underlying Health Conditions

PR Newswire October 21, 2020

CSL's Broad Response to COVID-19 and Advancements across the Company's Strategic Scientific Platforms are the Focus of Annual R&D Day

PR Newswire October 20, 2020

U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

PR Newswire September 28, 2020

Seqirus Publishes New Real-World Evidence (RWE) on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Vaccines

PR Newswire September 21, 2020

Seqirus Real World Evidence Published in Vaccine Highlights Value of Cell-Based Quadrivalent Influenza Vaccine in Preventing Influenza Related Hospitalizations in the U.S. 2017/18 Season

PR Newswire September 16, 2020

Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market

PR Newswire July 30, 2020

CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress

PR Newswire July 9, 2020

In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress

PR Newswire July 6, 2020

CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure

PR Newswire June 24, 2020

uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy

GlobeNewswire June 24, 2020

Yi Deng and Bill Mezzanotte Elected to University City Science Center Board of Directors

PR Newswire June 19, 2020

CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit

PR Newswire June 12, 2020

CSL Behring to Acquire Biotech Company Vitaeris

PR Newswire June 8, 2020

CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema

PR Newswire June 8, 2020

The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate

PR Newswire June 5, 2020

CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases

PR Newswire June 2, 2020